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Catheter thrombosis is a major limiting factor affectingcatheter survival in hemodialysis (HD). A previous
retrospective study highlighted the utility of outpatient
intradialytic high-dose urokinase (HDU) infusion in the
treatment of HD catheter thrombosis. The present study was
designed to prospectively evaluate the effectiveness of
250 000 IU urokinase given as a 3-hour infusion during HD.
The infusion would follow detection of a drop in blood flow
thought to be secondary to thrombosis [a "thrombotic event"
(TE)] after exclusion of nonthrombotic causes of drop in
blood flow [a "nonthrombotic event" (NTE)], such as systemic
hypotension or suboptimal position of the catheter on x ray.
An “event” was defined as a drop in pump blood flow by
greater than or equal to 20% of the prescribed blood flow.
Twenty patients (mean age 57.7 years; 13 males) with docu-
mented or potentially long-term catheters were recruited
(total catheters used, 30) from an outpatient HD unit. A
variety of catheter types were used. Catheter position was
confirmed on x ray. Hemodialysis sessions were monitored
for 6 months or until catheter removal (whichever was
earlier). Thrombotic and NTEs (mostly related to drop in
blood flow) were noted. The use of intradialytic HDU
infusions was monitored. Improvement was defined as re-
establishment of blood flow to within 10% of prescription.
There were 24 TEs in 11 patients and 15 NTEs in
7 patients. Twenty-one of 22 (95%) TEs responded to HDU,
with complete restoration of blood flow; in 1/22 HDU-treated
instances there was a partial response. For 2/24 TEs the
patients underwent catheter stripping with good results.
Twelve of 15 NTEs occurred in the first 2 weeks of catheter
placement versus 6/24 TEs (p = 0.001, chi-square). Catheter
survival was longer than 24 weeks in 12/30 catheters. Nine
catheters were lost to NTEs. No catheter was lost secondary
to a TE. It is therefore concluded that intradialytic outpatient
HDU is useful for the treatment of HD catheter thrombosis.
It may obviate/reduce the need for catheter stripping or
replacement. Randomized controlled trials with this approach
are needed. A higher proportion of NTEs tended to occur
earlier after catheter placement compared to TEs.
(Hemodial Int, Vol. 4, 32–36, 2000)
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Introduction
A recent editorial review elegantly summarized the importance
and optimal use of central venous catheters for hemodialysis
(HD) [1]. It highlighted the conundrum the nephrology
community faces today. Although it would be desirable to
provide native arteriovenous (AV) fistulas to a majority of
patients on chronic HD, as outlined in the Dialysis Outcomes
Quality Initiative (DOQI) guidelines [2], there will always
be a significant proportion of patients for whom a cuffed,
tunneled, central venous catheter is the only option,
particularly the elderly, diabetics with severe peripheral
vascular disease, and patients waiting for AV fistula maturation
[3,4]. Hence, there is an ongoing need for innovations in
design, insertion techniques, and strategies aimed at long-term
sustenance of these vital “life-lines.”
Although catheters have several advantages, they are beset
with two major complications in the form of thrombosis and
infection. These complications have had a negative impact
on the catheter’s potential role as viable long-term vascular
access in HD.
Catheter-related thrombosis can broadly be classified as
intraluminal (intrinsic) or extraluminal (extrinsic). The latter
can be a consequence of trauma to the endothelial lining of the
vein and subsequent thrombus formation, or of the frequent
development of a fibrin sleeve around the catheter, extending
from the point of entry of the catheter into the vein to the
catheter tip [5]. It is believed that this phenomenon contributes
significantly to the pathogenesis of catheter-related thrombosis.
A wide variety of intraluminal catheter locking strategies
have been used. The most popular are the heparin lock and
the urokinase lock. More recently, interest has been generated
in the concentrated citrate lock [6]. Although successful in
the short term, these regimens would, in theory, not be
efficacious against an extrinsic clot/fibrin sleeve, and there-
fore, are likely to have only limited utility in long-term
prevention and treatment of catheter-related thrombosis.
Since 1995 at the University of Missouri–Columbia and
Dialysis Clinic, Inc. (DCI), catheters malfunctioning due to
thrombosis have been successfully treated using an outpatient
high-dose urokinase (HDU) infusion in the absence of contra-
indications to its use. A dose of 250 000 IU of urokinase,
repeated for three consecutive dialyses, has been successful
as well as safe in restoring blood flow to that prescribed in
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99% of poor flow episodes, as reported in a retrospective
analysis by Twardowski [7]. The routine use of intradialytic
heparin was continued in all these patients without any
bleeding complications. Details of the protocol have been
published elsewhere [8].
In this paper, we report a prospective observational study
evaluating the use of HDU infusion in the outpatient HD
setting to see if this strategy would also be beneficial in
prolonging the useful life of HD catheters. In addition, we
looked at the role of warfarin as maintenance therapy to
prevent catheter thrombosis after the initial use of urokinase.
Patients and methods
The Institutional Review Board of the University Hospital
and Clinics, University of Missouri–Columbia, MO, U.S.A.,
approved the protocol. Patients were recruited from the DCI
outpatient unit between December 1997 and June 1999. These
were patients being initiated or maintained on chronic HD
with a central venous cuffed catheter as their only blood access
route, or awaiting maturation of an AV fistula, commencement
of peritoneal dialysis, or living donor transplantation.
Informed written consent was obtained from all patients.
Demographic data
Twenty patients were recruited over the study period. A total
of thirty catheters was utilized for these patients. Mean age
was 57.7 ± 13.9 (SD) years (range 28 – 81 years). There were
13 males and 7 females. Twelve were Caucasian, 7 African
American, and 1 Asian. The etiology of end-stage renal disease
(ESRD) was diabetes mellitus in 7, hypertension in 8, and
other causes in 5.
Indications, type of catheter, and site of insertion
The indications for using a cuffed, tunneled dialysis catheter
in these patients are shown in Table I. Sixteen patients had 24
PermCaths (Quinton Instrument Company, Seattle, WA,
U.S.A.), 1 patient had a Vas Cath (Bard, Salt Lake City, UT,
U.S.A.), 1 patient had 2 Tesio catheters (Medcomp,
Harleysville, PA, U.S.A.), 1 patient had an experimental
catheter manufactured by Quinton Instrument Company, and
2 patients had Opti-Flow catheters (Bard) placed during the
course of this study.
The sites of insertion were right internal jugular vein
(16 catheters), left internal jugular vein (5 catheters), left sub-
clavian vein (7 catheters), and right subclavian vein (2 catheters).
Catheter placement was performed in the operating room
by a dedicated team of vascular surgeons. Whether fluor-
oscopy was consistently used as an aid to catheter placement
was not recorded at the time of this data collection. Placement
of the catheter tip in the middle of the right atrium is the well-
known best location for ensuring consistently good blood
flows on dialysis. We determined catheter tip position by
inspection of routine postoperative chest radiographs and
measuring (in millimeters) the distance between the catheter
tip and the superior vena cava (SVC)–right atrial (RA)
junction. If the catheter was in the RA it was recorded as
“positive,” and if the tip of the catheter was in the SVC or
higher it was recorded as “negative.” “Zero” position implied
tip placement at the RA–SVC junction. The “arterial” and
“venous” tip distances from the RA–SVC junction were
recorded separately.
Monitoring catheter function
Long-term catheter survival was defined as continued optimal
catheter function for at least 24 weeks (6 months). Follow-up
of the study patients was planned for 6 months after catheter
insertion or until catheter removal, whichever was earlier. Any
complication was recorded, and reasons for catheter removal
were documented. All HD sessions were monitored closely.
Parameters recorded at half-hourly intervals included blood
flow rate (as measured by pump speed), arterial and venous
pressures, and systolic and diastolic blood pressure. An “event”
was defined as a persistent (continuously, for ≥ 1 hour during
dialysis) drop in blood flow by greater than or equal to 20%
below that prescribed. If catheter position, patient posture, or
a hypovolemic episode was found to be the explanation for
the drop in blood flow, it was designated a nonthrombotic event
(NTE), otherwise it was assumed to be secondary to catheter
malfunction due to possible thrombosis, that is, a thrombotic
event (TE). In the latter circumstance, in consultation with the
patient’s nephrologist and having ruled out the presence of
any contraindication to its use, the dialysis nurse administered
250 000 IU of urokinase, dissolved in 100 mL of normal saline,
over 3 hours via the venous chamber, with continuation of
dialysis and the routine intradialytic heparin protocol. The
usual protocol at our center stipulates that HDU infusion be
readministered during two further consecutive dialysis
treatments. It was so planned that if a patient required the use
of HDU for two TEs, he/she would be commenced on
prophylactic warfarin. International Normalized Ratio (INR)
was monitored by weekly predialysis blood sampling. Target
INR was 1.0 – 2.0, but was regulated upward in a stepwise
manner if the patient had further TEs [9].
Statistics
Descriptive statistics were employed for the most part in this
observational study. Fisher’s exact test was used to compare
TABLE I Indications for the use of cuffed, tunneled hemodialysis (HD)
catheters in this study.
Indication for HD catheter Patients (n)
Awaiting fistula maturation 8
Multiple failed arteriovenous accesses 5
Awaiting peritoneal dialysis 2
Awaiting living donor transplantation 2
Steal syndrome 1
Needle phobia 1
Patient preference 1
Total  20
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the incidence of NTE in “negatively”-placed catheters and
other catheters, and for comparison of early and late events.
A p value of less than 0.05 was considered statistically
significant.
Results
A total of 1239 outpatient dialysis treatments were monitored
during this study.
Catheter position data
Sixteen catheter tips were initially placed in a “negative”
position. Of these, 11 sustained NTEs (see below). Deter-
mination of the cause of NTE was uncertain, unless the patient
had significant hypovolemia and catheter function returned
to normal during the next dialysis without intervention other
than adjustment of target weight. Most NTEs were believed
to be due to poor position of the catheter. Six of the negatively-
placed catheters continued to function satisfactorily for 5 –
24 weeks; however, 5 of these subsequently had TEs. Only
4 NTEs occurred in the other 14 catheters. Most of these
events were believed to be related to hypovolemia. This
difference is not significant (p = 0.066).
Nonthrombotic events
There were 15 NTEs in 7 of the 20 patients (mean number of
events per affected patient, 2.1 ± 0.99; range 1 – 4). In five
instances there was no flow at the outset after initial catheter
placement. In one instance of primary nonfunction, the venous
limb of a Tesio catheter placed via the left internal jugular vein
became kinked in the subcutaneous tissue at the level of the
clavicle, and was repositioned successfully via the femoral route
by an interventional radiologist. In seven instances, poor blood
flow was felt to be due to faulty position of the catheter in the
SVC or brachiocephalic vein (“negatively”-placed catheters).
Other catheter complications
There was one severe exit-site infection requiring catheter
removal, and two separate instances of catheters being
accidentally cut by the patient: One patient presented to the
ER with a cut catheter for which an exact explanation could
not be elicited; the catheter had to be replaced. The other
patient sustained a cut on his second Tesio catheter 9 weeks
following catheter placement while attempting to cut off a
dressing with scissors. This was successfully repaired and the
catheter continued to function satisfactorily beyond 24 weeks.
Thrombotic events and use of high-dose urokinase
There were 24 (1.9%) instances of a drop in blood flow
presumed to be due to TE as there was no other obvious
explanation. These events occurred in 11 of the 20 patients
(mean number of events per affected patient, 2.18 ± 1.34; range
1 – 5). High-dose urokinase was administered in 22 of these
24 instances (the other two were managed by “catheter
stripping” with good results). However, not all TEs were
treated with the stipulated three consecutive doses, based on
the treating nephrologist’s judgement. In 19 TEs at least two
consecutive doses of HDU were given (9 instances of 2 doses
only, 7 instances of 3 doses, and 1 instance each of 4, 5, and
6 consecutive doses of HDU). In the last two instances
(i.e., where 5 and 6 doses of HDU were used), there was
possible accompanying catheter-related infection that was
being treated by intravenous antibiotics.
High-dose urokinase administration was associated with
complete recovery of blood flow on dialysis in 21 of the
22 HDU-treated instances of catheter malfunction thought to
be due to a TE (95%). There was partial restoration of blood
flow in 1 patient who received only 100 000 IU of urokinase
instead of 250 000 IU at the treating physician’s discretion.
The pre-HDU blood flows in these 22 instances of catheter
malfunction had decreased to a mean of 236.8 ± 84.5 mL/min.
Post-HDU blood flow increased to a mean of 431 ± 53.4 mL/
min. This resulted in satisfactory dialysis delivery in all these
patients. No side effects such as fever, allergic reactions, or
bleeding were observed as a result of HDU administration.
Early versus late events
Early events were defined as those occurring less than 2 weeks
after catheter placement. As depicted in Fig. 1, 12/15 NTEs
occurred early versus only 6/24 TEs (p = 0.001).
Warfarin data
Eight of the 11 patients who developed TEs were placed on
warfarin post-HDU, with target INR between 1 and 2. Six of
these 8 patients had catheter survival of longer than 24 weeks,
and the 2 remaining patients had elective removal of their
catheter, following maturation of their AV fistulas, at 20 weeks
and 14 weeks, respectively.
Catheter survival data
Causes of catheter loss are shown in Table II. No catheter was
lost secondary to a TE during this study. Catheter survival data
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FIGURE 1 Bar graph showing a comparison of early versus late events. Early
events were predominantly of the nonthrombotic (NTE) variety. Late events
were more often of a thrombotic (TE) nature.
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are shown in Fig. 2. Thirteen catheters were lost between 0
and 10 weeks (9 due to faulty initial positioning, 3 were elective
removals at access maturation, and 1 was lost to follow-up).
Twelve of 30 catheters survived more than 24 weeks.
Discussion
Low-dose intraluminal urokinase locks (5000 – 9000 IU/
lumen of catheter) have been in use since the late1980s and
have been reported to result in success rates of 74% – 95% in
keeping dialysis catheters patent [10,11]. Experience at the
University of Missouri with long-term catheters indicated that,
after several months of catheter use, such locks had only a
40% – 50% success rate [12]. The urokinase locks sometimes
have to be repeated several times [13] and result in time waste
in the outpatient dialysis unit. This not only increases cost of
care, but also compromises time on dialysis. In addition, this
strategy does not ensure long-term catheter survival.
Intraluminal-locking strategies are not useful in the
prevention or treatment of “extrinsic” thrombosis. They are
directed at intraluminal thrombi and cannot be expected to
have any major impact on fibrin sleeves or intramural thrombi
adhering to the venous wall. Although it is important to keep
the lumen of a dialysis catheter clot-free at all times by using
an effective locking system, it is vital to develop strategies
that will prevent or correct the abnormalities around the
catheter that predispose to thrombus formation. Strategies
aimed at retarding or eliminating the formation of a fibrin
sleeve could potentially enhance catheter survival.
We believe that, although not preventative, systemic
urokinase infusion is beneficial for attenuating extrinsic clots
and perhaps the fibrin sleeve, although our study does not
directly prove this point as no contrast imaging procedure
was used before or after HDU infusion. If this is combined
with maintenance therapy with warfarin, we feel that long-
term survival of permanent dialysis catheters can be improved
in patients who are predisposed to thrombotic complications.
To the best of our knowledge, this study is the first
prospective evaluation of outpatient use of HDU infusions
in the management of cuffed dialysis catheters. There have
been three prior retrospective studies [14–16] looking at this
issue.
Our study is not confirmatory owing to its observational
design. The number of patients who received warfarin after
having two or more TEs treated by HDU, versus those that did
not, is not sufficient to arrive at any definitive conclusions
about a potential prophylactic effect of warfarin. The
effectiveness of low-dose warfarin in preventing thrombotic
complications in infusion catheters has been determined in
several studies [17–19]. There are only a few retrospective
studies on the effectiveness of stepwise dosing of warfarin for
HD catheters [7,9,20]. Therefore, it would be desirable to
conduct a randomized, controlled clinical trial using the
approach of HDU followed by warfarin in patients who develop
catheter-related thrombosis. Future studies may evaluate the
optimal dose of urokinase, the number of infusions, and the
ideal INR range to prevent subsequent TEs.
In this uncontrolled, prospective observational study, we
confirmed our earlier observation in HD patients that HDU
does indeed improve suboptimal blood flows related to
thrombosis. In addition, we confirmed the safety of HDU, as
we did not encounter any complication related to its use. Of
course, it is imperative to systematically rule out both absolute
and relative contraindications for the use of a thrombolytic
agent prior to its use.
Another potential advantage to HDU is the relatively low
cost. Although we have not performed an updated cost
analysis, data have been published [8] showing HDU to be
considerably cheaper than either catheter stripping or surgical
replacement of a dialysis catheter at our center. Toward the
latter third of the study period, fresh supplies of urokinase
became unavailable and this study could not be continued.
However, we continued to use remaining supplies of urokinase
until June 1999.
Urokinase is not available at present and it is not known
when it will again become available. Although tissue plas-
minogen activator (tPA) is much more expensive than
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FIGURE 2 Bar chart showing the length of follow-up of patients with cuffed
tunneled catheters in this study. Patients were followed for a maximum of
24 weeks or loss of catheter, whichever was earlier. Between 0 and 10 weeks,
13 catheters were lost (9 secondary to nonthrombotic events, 3 to elective
removal, and 1 lost to follow-up). Between 11 and 15 weeks, 1 catheter was
electively removed. Of the 2 catheters lost between 16 and 20 weeks, 1 patient
was lost to follow-up and the other died. One elective removal and 1 loss to
follow-up accounted for 2 catheters that survived between 21 and 23 weeks.
TABLE II Causes of catheter loss during the course of this study. No catheter
was lost to a thrombotic event.
Reasons for catheter loss Catheters [n (%)]
Nonthrombotic event 9 (30)
Elective removal 3 (10)
Exit-site infection 1 (3)
Catheter cut accidentally 1 (3)
Patient lost to follow-up 3 (10)
Death 1 (3)
Thrombotic event 0 (0)
Total number of catheters 30
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urokinase, it may be the preferred fibrinolytic agent as it binds
to the clot, activates plasminogen in situ, and causes
fibrinolysis not only on the surface of a thrombus but also
within the thrombus [21]. In a study comparing the effective-
ness of a 2-mg lock with tPA to 10 000 IU of urokinase, tPA
was more effective [22]. Infusions of higher doses of tPA are
theoretically possible, and a systematic study of this agent
may be warranted despite the higher cost.
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